Complete financial analysis of USANA Health Sciences, Inc. (USNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of USANA Health Sciences, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Yowie Group Limited (YOW.AX) Income Statement Analysis – Financial Results
- Surgical Science Sweden AB (publ) (SUS.ST) Income Statement Analysis – Financial Results
- VYNE Therapeutics Inc. (VYNE) Income Statement Analysis – Financial Results
- Cofina, SGPS, S.A. (CFN.LS) Income Statement Analysis – Financial Results
- Simmons First National Corporation (SFNC) Income Statement Analysis – Financial Results
USANA Health Sciences, Inc. (USNA)
About USANA Health Sciences, Inc.
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 921.01M | 998.60M | 1.19B | 1.13B | 1.06B | 1.19B | 1.05B | 1.01B | 918.50M | 790.47M | 718.18M | 648.73M | 581.94M | 517.64M | 436.94M | 429.01M | 423.15M | 374.19M | 327.74M | 272.82M | 200.01M | 133.78M | 114.28M | 123.18M | 129.40M | 121.60M | 85.20M | 56.70M | 24.50M | 7.30M |
| Cost of Revenue | 176.69M | 193.89M | 217.90M | 209.11M | 187.50M | 200.71M | 179.40M | 180.19M | 159.68M | 140.79M | 127.44M | 115.80M | 101.69M | 95.48M | 89.80M | 88.88M | 87.89M | 89.55M | 78.02M | 66.82M | 44.42M | 33.39M | 32.80M | 32.16M | 21.00M | 21.90M | 15.60M | 10.80M | 5.40M | 0.00 |
| Gross Profit | 744.32M | 804.71M | 968.57M | 925.53M | 873.40M | 988.54M | 867.86M | 825.89M | 758.82M | 649.68M | 590.74M | 532.92M | 480.25M | 422.16M | 347.14M | 340.13M | 335.26M | 284.65M | 249.73M | 206.00M | 155.59M | 100.38M | 81.48M | 91.02M | 108.40M | 99.70M | 69.60M | 45.90M | 19.10M | 7.30M |
| Gross Profit Ratio | 80.82% | 80.58% | 81.63% | 81.57% | 82.33% | 83.12% | 82.87% | 82.09% | 82.61% | 82.19% | 82.26% | 82.15% | 82.53% | 81.55% | 79.45% | 79.28% | 79.23% | 76.07% | 76.20% | 75.51% | 77.79% | 75.04% | 71.30% | 73.89% | 83.77% | 81.99% | 81.69% | 80.95% | 77.96% | 100.00% |
| Research & Development | 11.45M | 11.56M | 11.11M | 10.63M | 10.26M | 10.24M | 8.95M | 8.84M | 6.42M | 5.13M | 5.08M | 4.66M | 0.00 | 0.00 | 0.00 | 0.00 | 3.36M | 3.20M | 2.34M | 2.03M | 1.38M | 1.04M | 1.08M | 1.41M | 1.40M | 1.40M | 1.20M | 800.00K | 300.00K | 0.00 |
| General & Administrative | 256.99M | 262.30M | 279.11M | 261.19M | 267.73M | 275.06M | 265.09M | 234.19M | 209.00M | 184.53M | 166.21M | 154.24M | 402.99M | 353.95M | 296.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 434.79M | 519.27M | 487.86M | 459.48M | 525.13M | 470.26M | 453.08M | 408.16M | 349.04M | 307.82M | 280.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 256.99M | 697.10M | 798.37M | 749.04M | 727.21M | 800.19M | 735.36M | 687.27M | 617.16M | 533.58M | 474.03M | 434.74M | 402.99M | 353.95M | 296.35M | 292.14M | 261.19M | 219.11M | 189.02M | 159.13M | 123.09M | 86.56M | 76.20M | 79.97M | 88.50M | 79.70M | 55.60M | 36.40M | 15.00M | 0.00 |
| Other Expenses | 382.81M | 1.01M | 450.00K | 1.46M | 4.31M | 3.16M | 2.14M | -70.00K | 927.00K | -449.00K | -131.00K | 247.00K | 164.24M | 137.71M | 106.56M | 89.43M | 82.49M | 56.71M | 50.68M | 37.61M | 34.25M | 17.78M | 11.11M | 4.19M | 4.50M | 3.40M | 2.20M | 800.00K | 300.00K | 0.00 |
| Operating Expenses | 651.25M | 697.10M | 798.37M | 749.04M | 727.21M | 800.19M | 735.36M | 687.27M | 617.16M | 533.58M | 474.03M | 434.74M | 402.99M | 353.95M | 296.35M | 292.14M | 264.56M | 222.30M | 191.36M | 161.16M | 124.47M | 87.59M | 77.28M | 85.57M | 94.40M | 84.50M | 59.00M | 38.00M | 15.60M | 0.00 |
| Cost & Expenses | 827.94M | 890.99M | 1.02B | 958.15M | 914.71M | 1.00B | 914.76M | 867.46M | 776.84M | 674.37M | 601.46M | 550.55M | 504.68M | 449.43M | 386.15M | 381.02M | 352.45M | 311.85M | 269.38M | 227.98M | 168.89M | 120.98M | 110.08M | 117.73M | 115.40M | 106.40M | 74.60M | 48.80M | 21.00M | 0.00 |
| Interest Income | 9.64M | 3.79M | 2.52M | 2.54M | 4.71M | 4.43M | 2.19M | 1.48M | 1.12M | 500.00K | 464.00K | 247.00K | 191.00K | 167.00K | 82.00K | 249.00K | 0.00 | 0.00 | 0.00 | 572.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 262.00K | 192.00K | 57.00K | 507.00K | 66.00K | 36.00K | 46.00K | 444.00K | 15.00K | 129.00K | 1.00K | 20.00K | 9.00K | 94.00K | 609.00K | 792.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 20.40M | 21.41M | 22.19M | 22.51M | 22.79M | 16.73M | 15.96M | 13.48M | 9.98M | 8.81M | 9.04M | 8.83M | 8.47M | 7.92M | 7.07M | 6.70M | 5.33M | 5.56M | 5.90M | 4.84M | 3.88M | 4.14M | 4.12M | 4.19M | 4.50M | 3.40M | 2.20M | 800.00K | 300.00K | 0.00 |
| EBITDA | 123.11M | 130.22M | 192.89M | 200.96M | 146.19M | 188.35M | 132.50M | 152.10M | 151.64M | 124.91M | 125.76M | 107.27M | 85.96M | 76.87M | 58.66M | 53.81M | 76.03M | 69.43M | 64.77M | 49.92M | 31.12M | 12.79M | 4.20M | 5.46M | 18.50M | 18.60M | 12.80M | 8.70M | 3.80M | 7.30M |
| EBITDA Ratio | 13.37% | 10.78% | 14.34% | 15.55% | 13.78% | 15.84% | 12.65% | 13.78% | 15.42% | 14.69% | 16.25% | 15.13% | 13.24% | 13.05% | 11.58% | 13.01% | 17.80% | 17.92% | 19.63% | 18.34% | 17.44% | 12.65% | 7.30% | 7.52% | 17.70% | 15.13% | 14.79% | 14.81% | 14.69% | 100.00% |
| Operating Income | 93.07M | 107.61M | 170.19M | 176.49M | 146.19M | 188.35M | 132.50M | 138.62M | 141.66M | 116.10M | 116.71M | 98.18M | 77.26M | 68.22M | 50.79M | 48.00M | 70.70M | 62.34M | 58.36M | 44.85M | 31.12M | 12.79M | 4.20M | 5.46M | 14.00M | 15.20M | 10.60M | 7.90M | 3.50M | 7.30M |
| Operating Income Ratio | 10.11% | 10.78% | 14.34% | 15.55% | 13.78% | 15.84% | 12.65% | 13.78% | 15.42% | 14.69% | 16.25% | 15.13% | 13.28% | 13.18% | 11.62% | 11.19% | 16.71% | 16.66% | 17.81% | 16.44% | 15.56% | 9.56% | 3.68% | 4.43% | 10.82% | 12.50% | 12.44% | 13.93% | 14.29% | 100.00% |
| Total Other Income/Expenses | 9.38M | 1.01M | 450.00K | 1.46M | 4.31M | 3.16M | 2.14M | -70.00K | 927.00K | -449.00K | -131.00K | 247.00K | 222.00K | 648.00K | 187.00K | -1.68M | 471.00K | 1.41M | 487.00K | 233.00K | 192.00K | -221.00K | -692.00K | -677.00K | -4.45M | 200.00K | 100.00K | 200.00K | 200.00K | -7.30M |
| Income Before Tax | 102.45M | 108.62M | 170.64M | 177.95M | 150.50M | 191.51M | 134.64M | 138.55M | 142.59M | 115.65M | 116.58M | 98.43M | 77.48M | 68.86M | 50.98M | 46.32M | 71.17M | 63.75M | 58.85M | 45.08M | 31.31M | 12.57M | 3.51M | 4.78M | 9.60M | 15.40M | 10.70M | 8.10M | 3.70M | 0.00 |
| Income Before Tax Ratio | 11.12% | 10.88% | 14.38% | 15.68% | 14.19% | 16.10% | 12.86% | 13.77% | 15.52% | 14.63% | 16.23% | 15.17% | 13.31% | 13.30% | 11.67% | 10.80% | 16.82% | 17.04% | 17.96% | 16.52% | 15.65% | 9.40% | 3.07% | 3.88% | 7.42% | 12.66% | 12.56% | 14.29% | 15.10% | 0.00% |
| Income Tax Expense | 38.67M | 39.27M | 54.14M | 53.28M | 49.97M | 65.29M | 72.11M | 38.51M | 47.92M | 39.02M | 37.56M | 31.99M | 26.73M | 23.21M | 17.42M | 16.38M | 25.24M | 22.49M | 19.86M | 14.30M | 10.49M | 4.07M | 1.31M | 1.91M | 3.70M | 5.90M | 4.10M | 3.10M | 1.40M | -300.00K |
| Net Income | 63.79M | 69.35M | 116.51M | 124.66M | 100.53M | 126.22M | 62.54M | 100.04M | 94.67M | 76.64M | 79.02M | 66.43M | 50.75M | 45.65M | 33.56M | 29.95M | 45.32M | 41.27M | 38.99M | 30.78M | 20.82M | 8.50M | 2.20M | 2.87M | 5.90M | 9.50M | 6.60M | 5.00M | 2.30M | 300.00K |
| Net Income Ratio | 6.93% | 6.94% | 9.82% | 10.99% | 9.48% | 10.61% | 5.97% | 9.94% | 10.31% | 9.69% | 11.00% | 10.24% | 8.72% | 8.82% | 7.68% | 6.98% | 10.71% | 11.03% | 11.90% | 11.28% | 10.41% | 6.36% | 1.92% | 2.33% | 4.56% | 7.81% | 7.75% | 8.82% | 9.39% | 4.11% |
| EPS | 3.31 | 3.60 | 5.78 | 5.89 | 4.44 | 5.36 | 2.60 | 4.09 | 3.71 | 3.11 | 2.85 | 2.40 | 1.70 | 1.43 | 1.10 | 0.94 | 1.36 | 1.15 | 1.03 | 0.81 | 0.55 | 0.23 | 0.06 | 0.07 | 0.12 | 0.18 | 0.13 | 0.10 | 0.05 | 0.01 |
| EPS Diluted | 3.30 | 3.59 | 5.73 | 5.86 | 4.41 | 5.12 | 2.53 | 3.99 | 3.59 | 2.80 | 2.78 | 2.23 | 1.63 | 1.43 | 1.09 | 0.93 | 1.32 | 1.10 | 0.99 | 0.76 | 0.49 | 0.21 | 0.06 | 0.07 | 0.12 | 0.17 | 0.12 | 0.10 | 0.05 | 0.01 |
| Weighted Avg Shares Out | 19.25M | 19.25M | 20.15M | 21.16M | 22.64M | 23.57M | 24.02M | 24.49M | 24.98M | 25.27M | 27.77M | 27.64M | 29.88M | 30.62M | 30.70M | 32.10M | 33.47M | 36.11M | 37.75M | 38.33M | 38.04M | 37.77M | 38.71M | 39.15M | 48.63M | 51.75M | 50.96M | 50.00M | 43.81M | 40.00M |
| Weighted Avg Shares Out (Dil) | 19.35M | 19.31M | 20.34M | 21.26M | 22.82M | 24.64M | 24.71M | 25.05M | 26.35M | 27.38M | 28.41M | 29.85M | 31.15M | 31.88M | 30.86M | 32.33M | 34.41M | 37.45M | 39.44M | 40.83M | 42.64M | 41.29M | 38.82M | 39.56M | 49.89M | 55.72M | 53.28M | 52.63M | 46.00M | 40.00M |
USANA Executive Chairman Kevin Guest Calls on Communities to Celebrate National Build Joy Day
Spread Kindness, Happiness Through Five Meaningful Acts of Generosity SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Kevin Guest is encouraging everyone to come together to celebrate National Build Joy Day today by spreading kindness and uplifting their communities...
USANA Named Top Manufacturer in Utah for Third Time
SALT LAKE CITY , Nov. 12, 2024 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in nutrition, was recently awarded Manufacturer of the Year for the third consecutive year by the Utah Manufacturers Association in the "mega-sized (500+ employees)...
USANA Executive Chairman Kevin Guest Celebrates Gratitude Month
SALT LAKE CITY , Nov. 1, 2024 /PRNewswire/ -- This November, a multinational leader is encouraging people everywhere to celebrate National Gratitude Month and experience the profound impact gratitude has on health and happiness. From enhancing psychological well-being to boosting physical...
USANA Health Sciences, Inc. (USNA) Q3 2024 Earnings Call Transcript
USANA Health Sciences, Inc. (NYSE:USNA ) Q3 2024 Earnings Call Transcript October 23, 2024 11:00 AM ET Company Participants Andrew Masuda - IR Jim Brown - President and CEO Douglas Hekking - CFO Brent Neidig - CCO Conference Call Participants...
USANA Health Sciences (USNA) Q3 Earnings Surpass Estimates
USANA Health Sciences (USNA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.
USANA Health Sciences Reports Third Quarter 2024 Results
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 28, 2024. Key Financial & Operating Results Third quarter net sales were $200 million versus $213 million during Q3 2023....
10 small-cap stocks selected by digging deep for quality
David Trainer explains how New Constructs incorporates decades of information buried in companies' financial statement notes, for “better” calculations of returns on invested capital
11 USANA Products Now Listed on Prestigious Prescribers' Digital Reference®
SALT LAKE CITY , Oct. 10, 2024 /PRNewswire/ -- USANA Health Sciences, Inc. is proud to announce that the Prescribers' Digital Reference® (PDR) has recently included 11 of USANA's products to their list of trusted drugs and supplements. This recognition adds further...
USANA Schedules Third Quarter 2024 Earnings Release and Conference Call
SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company's earnings release, the Company will...
USANA Executive Chairman Kevin Guest Celebrates Country Music Month, Mental Balance
SALT LAKE CITY , Oct. 1, 2024 /PRNewswire/ -- As vibrant melodies of Country Music Month fill the air this October, there is no better time to explore the symphony between our love for music and the pursuit of mental wellness....
Source: https://incomestatements.info
Category: Stock Reports